# SUPERIOR: arrhythmia recurrence after ablation 18% on sacubitril/valsartan vs 28.3% on valsartan

- Published: 2026-11-08 23:47 UTC
- Section: Life & Health › Medicine
- Tags: SUPERIOR trial, atrial fibrillation recurrence, sacubitril/valsartan after ablation, valsartan monotherapy, catheter ablation hypertension, American Heart Association 2026, paroxysmal atrial fibrillation, atrial tachyarrhythmia
- URL: https://realtech.media/news/rt-3d21bad9df6230b9489cdf29_superior_arrhythmia_recurrence/

**In a randomized trial of 320 older hypertensive patients in China, the combination lowered recurrence at 12 months; blood pressure fell equally. Data are preliminary.**

![SUPERIOR: arrhythmia recurrence after ablation 18% on sacubitril/valsartan vs 28.3% on valsartan](https://realtech.media/media/2026/11/91b032efc04ad200.webp)
*lomazoma.com*

Results of the SUPERIOR trial were presented on 6 November 2026 at the American Heart Association Scientific Sessions in Chicago, according to lomazoma.com. The randomized study compared a combination of sacubitril/valsartan with valsartan monotherapy in older patients with hypertension after catheter ablation for atrial fibrillation. After 12 months, documented recurrence of atrial arrhythmias was 18% in the combination group and 28.3% in the valsartan group [1].

## Study design and participants

The trial enrolled 320 adults from China aged at least 55 years. The mean age of the cohort was 68 years, and women made up 41.2%. About 66.6% of participants had paroxysmal atrial fibrillation [1].

All participants underwent catheter ablation between February 2023 and January 2025. One group then received sacubitril/valsartan at 100 mg once daily. The control group received valsartan alone at 80 mg once daily [1].

The primary endpoint was the occurrence of documented atrial tachyarrhythmias during a 12-month follow-up [1].

## Blood pressure and limitations

Both regimens lowered blood pressure to a similar degree. Systolic pressure fell by about 10 mm Hg in each group, and 24-hour ambulatory monitoring showed no significant difference between them [1]. The better rhythm stability in the combination group therefore appeared without a substantially different overall reduction in blood pressure [1].

The results are preliminary. They were presented as a conference abstract and have not yet passed regular peer review [1].

The study documents also note methodological limitations. The trial was open-label, with intermittent rhythm monitoring. The cohort was limited to older hypertensive patients in China, so applicability to other patient groups requires further clinical verification [1].

## Sources

1. [lomazoma.com](https://lomazoma.com/herzrhythmus-nach-ablation-18-statt-283-prozent-rueckfaelle-bei-kombinationstherapie)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-3d21bad9df6230b9489cdf29_superior_arrhythmia_recurrence/